Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.97
-1.60 (-5.60%)
At close: Feb 27, 2026, 4:00 PM EST
26.70
-0.27 (-1.00%)
After-hours: Feb 27, 2026, 6:54 PM EST
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$1,099,626
Profits / Employee
-$47,196
Market Cap
3.35B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| Denali Therapeutics | 517 |
| Tarsus Pharmaceuticals | 370 |
| Xenon Pharmaceuticals | 327 |
| Vera Therapeutics | 224 |
| Alumis | 223 |
ARQT News
- 1 day ago - Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - GlobeNewsWire
- 2 days ago - Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
- 2 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 days ago - Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments - GlobeNewsWire
- 8 days ago - Arcutis After The Double: Hypergrowth Peaks, Compounding Remains - Seeking Alpha
- 23 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis - GlobeNewsWire